1. Home
  2. WYY vs ICCC Comparison

WYY vs ICCC Comparison

Compare WYY & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo WidePoint Corporation

WYY

WidePoint Corporation

HOLD

Current Price

$9.95

Market Cap

107.8M

Sector

Technology

ML Signal

HOLD

Logo ImmuCell Corporation

ICCC

ImmuCell Corporation

N/A

Current Price

$9.91

Market Cap

93.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
WYY
ICCC
Founded
1991
1982
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
107.8M
93.1M
IPO Year
2005
1995

Fundamental Metrics

Financial Performance
Metric
WYY
ICCC
Price
$9.95
$9.91
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$8.67
N/A
AVG Volume (30 Days)
126.5K
27.5K
Earning Date
05-14-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
53.85
EPS
0.01
0.41
Revenue
$150,545,364.00
$26,493,169.00
Revenue This Year
$14.41
N/A
Revenue Next Year
$11.41
N/A
P/E Ratio
$1,018.00
$24.44
Revenue Growth
5.59
51.64
52 Week Low
$3.96
$4.52
52 Week High
$24.30
$12.10

Technical Indicators

Market Signals
Indicator
WYY
ICCC
Relative Strength Index (RSI) 47.22 42.02
Support Level $9.53 $9.36
Resistance Level $10.49 $10.75
Average True Range (ATR) 0.61 0.45
MACD 0.10 -0.07
Stochastic Oscillator 45.99 29.56

Price Performance

Historical Comparison
WYY
ICCC

About WYY WidePoint Corporation

WidePoint Corp is a provider of Technology Management as a Service (TMaaS) that consists of federally certified communications management, identity management, interactive bill presentment and analytics, and an Information Technology as a Service solution. Its solutions include Telecom Lifecycle Management, Digital billing communications solutions, and Mobile and Identity management. Geographically, the company generates a majority of its revenue from the United States and the rest from Europe.

About ICCC ImmuCell Corporation

ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.

Share on Social Networks: